Unfortunately, in a number of patients, IM has a lower efficiency in the advanced stages of CML due to the apparition of mutations that amplify the BCR-ABL gene expression and thus the development of IM resistance. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.